Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

CCX-2B, a Biotin-Modified Near Infrared Probe Enable Tumor-Specific Imaging of Viscosity and Sulfite.

Created on 18 Nov 2026

Authors

Shuanglong Li, Shun Li, Ruping Li, Yue Tan, Xinrui Li, Xiujuan Zhao, Jiaqiang Wu, Chunli Xia, Daoyuan Chen

Published in

Analytical chemistry. Volume 98. Issue 45. Pages 32675-32685. Nov 17, 2026.

Abstract

Aberrant viscosity and sulfur dioxide (SO2) metabolism are closely associated with cancer. Nevertheless, there remains a scarcity of near-infrared probes that can monitor the in-vivo dynamics of both viscosity and SO2-derived sulfite (SO32-) while exerting cancer-targeting performance. Herein, we report the development of CCX-2B, a biotin-modified hemicyanine probe constructed through the condensation of indolium and coumarin analogues. CCX-2B displays high sensitivity and selectivity toward both viscosity and sulfite, with limits of detection of 1.67 cP (viscosity) and 8.9 nM (sulfite), respectively. Moreover, it can distinguish cancer cells from normal cells, monitor drug-triggered intracellular viscosity fluctuations, enable intracellular visualization of exogenous and endogenous sulfite, and preferentially accumulate in tumor tissues following intravenous administration. Collectively, CCX-2B represents a promising near-infrared probe for tracking both viscosity and sulfite dynamics, featuring favorable tumor-targeting capability for bioimaging applications.

PMID:
43046410
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement